List of Excipients in Branded Drug ATELVIA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	ATELVIA	risedronate sodium	0430-0979	CELLULOSE, MICROCRYSTALLINE
Allergan Inc	ATELVIA	risedronate sodium	0430-0979	EDETATE DISODIUM
Allergan Inc	ATELVIA	risedronate sodium	0430-0979	FERRIC OXIDE YELLOW
Allergan Inc	ATELVIA	risedronate sodium	0430-0979	MAGNESIUM STEARATE

Atelvia Excipient Strategy and Commercial Opportunities for Risedronate Delayed-Release Tablets

Last updated: August 4, 2026

Atelvia is a 35 mg delayed-release tablet containing risedronate sodium, a bisphosphonate used for postmenopausal osteoporosis. Its commercial differentiation is based on enteric protection and administration after breakfast, unlike immediate-release risedronate products that require fasting administration. The principal opportunity is not a new active ingredient. It is a lower-cost, bioequivalent delayed-release product with reliable enteric performance, robust coating manufacture, and a simplified excipient system.

What is Atelvia and how does its formulation differ from Actonel?

Atelvia contains risedronate sodium in a delayed-release, enteric-coated tablet. FDA approved Atelvia in 2010 under NDA 022560 for once-weekly administration after breakfast in postmenopausal women with osteoporosis.[1]

Attribute	Atelvia	Immediate-release risedronate
Active ingredient	Risedronate sodium	Risedronate sodium
Strength	35 mg	Commonly 5 mg, 30 mg, and 35 mg
Dosage form	Delayed-release tablet	Immediate-release tablet
Administration	Immediately after breakfast	At least 30 minutes before food or drink
Primary formulation technology	Enteric-coated tablet	Conventional immediate-release tablet
Food strategy	Designed for post-breakfast administration	Food reduces absorption
Commercial differentiation	Convenience and food-compatible dosing	Established low-cost generic category

Atelvia was developed to reduce the administration burden associated with oral bisphosphonates. Its formulation delays drug release until the tablet reaches the intestinal environment, where risedronate absorption is less affected by food than gastric administration would be.

The product is not interchangeable with immediate-release risedronate solely because both products contain risedronate sodium. Delayed-release performance, dosing instructions, labeling, and regulatory standards are product-specific.

What excipients are used in Atelvia?

Atelvia uses a conventional tablet core combined with an enteric coating system. The FDA-approved labeling identifies inactive ingredients that include tablet binders, diluents, disintegrants, lubricants, glidants, film-coating materials, and enteric-coating components.[1]

Atelvia excipient architecture

The formulation can be analyzed in four functional layers:

1. Tablet core

   • Microcrystalline cellulose
   • Lactose monohydrate
   • Crospovidone
   • Povidone
   • Magnesium stearate
   • Colloidal silicon dioxide

2. Immediate protective or film-coating layer

   • Hypromellose
   • Polyethylene glycol
   • Titanium dioxide

3. Enteric coating

   • Methacrylic acid copolymer
   • Talc
   • Triethyl citrate

4. Manufacturing controls

   • Compression force
   • Tablet hardness
   • Coating weight gain
   • Acid-stage resistance
   • Buffer-stage release
   • Moisture control

The precise excipient grade can be commercially important. A generic sponsor may use the same chemical excipient but a different particle-size distribution, viscosity grade, plasticizer level, or polymer dispersion. Those changes can affect granulation, tablet strength, coating uniformity, dissolution, and stability.

Why the excipient system matters

Risedronate is highly water-soluble, but oral bisphosphonate performance depends heavily on administration conditions and absorption limitations. The enteric film must prevent meaningful release in the stomach while permitting prompt release at the intended intestinal pH.

A failure in any of the following areas can create regulatory or commercial risk:

• Premature release during the acid stage
• Delayed release after buffer exposure
• Poor adhesion of the enteric film
• Tablet cracking during packaging or transport
• Moisture-driven changes in coating performance
• Increased variability after scale-up
• Interaction between coating polymers and the tablet core
• Excipient incompatibility with risedronate sodium

The main formulation barrier is therefore process control rather than molecular novelty.

What excipient strategy creates the strongest commercial opportunity?

The most attractive strategy is a validated, low-complexity enteric system that preserves Atelvia’s food-compatible dosing profile while reducing manufacturing cost.

1. Optimize the enteric polymer system

Methacrylic acid copolymers are established pharmaceutical enteric polymers. A generic manufacturer can evaluate:

• Methacrylic acid-ethyl acrylate copolymers
• Methacrylic acid-methyl methacrylate copolymers
• Aqueous polymer dispersions
• Organic-solvent coating systems
• Alternative plasticizer and anti-tacking combinations

The opportunity lies in reducing coating weight while maintaining acid resistance. Lower coating weight can improve throughput, shorten drying time, and reduce tablet size. It also can lower raw-material costs.

The technical target is not the cheapest coating. It is the lowest total cost that meets dissolution, stability, and bioequivalence requirements.

2. Replace or simplify excipients where regulatory risk is manageable

Potential optimization targets include:

• Replacing lactose with a direct-compression filler
• Reducing colloidal silicon dioxide through improved powder flow
• Replacing povidone with a lower-viscosity binder
• Using a multifunctional co-processed excipient
• Reducing coating-layer complexity
• Selecting a lower-cost equivalent enteric polymer grade

The highest-value changes are those that reduce process steps without changing the release mechanism. A sponsor should avoid unnecessary substitution of multiple excipients at once because it increases formulation-development variables and may complicate comparative dissolution work.

3. Improve coating efficiency

Coating is likely to be the largest manufacturing cost center beyond active pharmaceutical ingredient costs. Commercial improvements may come from:

• Higher solids-content coating suspensions
• Improved spray-nozzle configuration
• Reduced atomization air
• Better tablet-bed mixing
• Continuous coating equipment
• In-line weight-gain monitoring
• Automated endpoint detection
• Lower drying-air energy demand

The ability to manufacture a consistent enteric coat at commercial scale can become a stronger competitive advantage than nominal excipient cost.

4. Develop a differentiated packaging system

Risedronate products require protection from moisture and physical damage. Commercial opportunities include:

• High-barrier blister packaging
• Unit-dose packaging
• Desiccant-assisted bottles
• Child-resistant packaging
• Calendarized weekly-dose packaging
• Senior-friendly labeling and opening systems

Packaging can support adherence without changing the drug product. A calendar blister may be particularly suitable for once-weekly administration, although the added packaging cost must be justified by payer, pharmacy, or patient demand.

What formulation patents protect Atelvia?

Atelvia’s differentiation is associated with delayed-release risedronate formulation technology, not with a new chemical entity. The relevant intellectual-property categories are:

• Delayed-release risedronate compositions
• Enteric-coated tablets
• Administration of risedronate after food
• Dissolution profiles and acid resistance
• Pharmaceutical combinations involving risedronate and food or mineral components
• Manufacturing processes for coated bisphosphonate tablets

The core commercial question is whether relevant formulation claims remain enforceable and listed for the specific 35 mg delayed-release product. FDA Orange Book entries, patent certifications, and litigation records control the practical generic-entry analysis.[2]

A formulation patent can be commercially meaningful even when the active ingredient is long off patent. Its strength depends on claim scope, written-description support, prosecution history, validity under obviousness standards, and whether a generic can design around the claimed coating, composition, or dissolution profile.

How strong is the Atelvia patent estate?

The estate should be viewed as narrower than a new-molecule patent estate because:

• Risedronate sodium is an established active ingredient.
• Enteric coating is a well-known pharmaceutical technique.
• Multiple polymers and coating processes may provide design-around routes.
• Bioequivalence may be demonstrated through comparative dissolution and pharmacokinetic testing.
• Product-by-process limitations may be vulnerable if the finished product can be made by another process.

The strongest potential claims would be those tied to a specific combination of delayed-release performance, post-breakfast administration, and clinically relevant exposure. Broad claims covering any enteric-coated risedronate tablet would face greater validity and design-around pressure.

When does Atelvia lose exclusivity?

Atelvia’s regulatory exclusivity and patent exclusivity are separate.

Exclusivity category	Atelvia relevance
New chemical entity exclusivity	Generally unavailable because risedronate was previously approved
Three-year exclusivity	Potentially relevant to the approval of a new clinical formulation, depending on FDA determination
Patent exclusivity	Depends on issued formulation and method-of-use patents
Orange Book protection	Depends on active listings for the approved product
Generic approval pathway	An ANDA may rely on the reference product’s safety and efficacy findings

The FDA approved Atelvia in 2010.[1] The commercial entry date for a generic depends on the latest enforceable patent, the nature of any Paragraph IV certification, litigation, settlement terms, and the generic applicant’s regulatory status. Approval of an immediate-release risedronate generic does not establish approval of a delayed-release Atelvia equivalent.

A precise launch forecast requires current Orange Book data and court records. The strategic implication is clear: the relevant barrier is the delayed-release product’s patent and regulatory file, not the older Actonel or generic risedronate landscape.

What Paragraph IV challenges and litigation affect Atelvia?

A generic applicant can file an ANDA with a Paragraph IV certification asserting that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The reference-product sponsor may then bring a patent-infringement action under the Hatch-Waxman framework.

For Atelvia, litigation risk would likely center on:

• Whether the proposed generic has the same delayed-release characteristics
• Whether the generic infringes composition or coating claims
• Whether the listed patent claims are obvious in view of conventional enteric technology
• Whether post-breakfast dosing is protected by method-of-use claims
• Whether the ANDA label includes a carve-out for patented indications
• Whether the generic’s dissolution profile falls within claimed ranges

Settlement agreements can include:

• A license with a fixed future launch date
• A royalty-bearing license
• A supply arrangement
• A covenant not to sue
• Restrictions on launch strength or dosage form
• Authorized-generic terms

Atelvia’s litigation profile should be monitored through FDA patent certifications, district-court dockets, the Federal Trade Commission’s pharmaceutical settlement reports, and Orange Book revisions.[2-4]

What is the FDA regulatory status of Atelvia?

Atelvia is an FDA-approved prescription delayed-release tablet containing risedronate sodium. Its labeled indication is treatment of postmenopausal osteoporosis in women.[1]

The product’s regulatory value is linked to three attributes:

1. The approved 35 mg strength.
2. Delayed-release performance.
3. Administration immediately after breakfast.

A follow-on product must demonstrate pharmaceutical equivalence and bioequivalence under the applicable ANDA requirements. The sponsor must also address:

• Same active ingredient
• Same dosage form
• Same strength
• Same route of administration
• Comparable quality and performance
• Labeling differences permitted under the ANDA framework
• Enteric dissolution testing
• Stability through the proposed shelf life

Because the product’s differentiation is release timing, comparative dissolution is likely to receive close attention during development. A formulation that is chemically equivalent but releases too early or too late may fail to replicate the reference product’s performance.

What generic entry risks exist for Atelvia?

Low-cost generic substitution

Once delayed-release risedronate competition is available, price erosion can be substantial. The active ingredient is off-patent and multiple manufacturers can source risedronate sodium. The main barrier is the formulation and regulatory package.

Authorized generic risk

A brand owner may launch an authorized generic to retain channel access and limit third-party generic share. An authorized generic can use the brand product or a closely related formulation and may enter under a commercial license.

Formulation failure risk

The most significant development risks are:

• Inadequate acid-stage protection
• Failure to match buffer-stage release
• Coating defects
• Inconsistent tablet hardness
• Moisture sensitivity
• Inability to scale the coating process
• Bioequivalence failure caused by formulation or food effects

Substitution risk from other osteoporosis drugs

Atelvia competes with:

• Generic immediate-release risedronate
• Alendronate tablets
• Zoledronic acid injection
• Denosumab
• Oral ibandronate
• Other osteoporosis therapies, including anabolic and sclerostin-targeted products

Atelvia’s strongest commercial position is among patients who value post-breakfast weekly dosing but do not require injectable treatment.

How does Atelvia compare with competing oral bisphosphonates?

Product	Dosing constraint	Enteric technology	Generic competition	Commercial implication
Atelvia	After breakfast	Yes	Delayed-release-specific	Convenience-based differentiation
Immediate-release risedronate	Fasting, upright administration	No	Established	Lower-cost substitute
Alendronate	Fasting, upright administration	No	Extensive	Strong price pressure
Ibandronate	Monthly oral dosing	No	Generic competition	Different adherence proposition

Atelvia’s value proposition is operational convenience, not superior active-ingredient potency. That distinction limits premium pricing unless the product demonstrates better adherence, persistence, or patient preference.

What licensing and partnership opportunities exist?

Potential partners include:

• Generic pharmaceutical companies with enteric-coating capacity
• Contract development and manufacturing organizations
• Excipient suppliers with controlled-release polymer platforms
• Packaging companies specializing in weekly-dose adherence systems
• Regional licensees in markets where delayed-release risedronate has limited competition
• Specialty-pharma companies focused on osteoporosis

A licensing transaction could cover:

• Formulation know-how
• Coating process parameters
• Analytical methods
• Regulatory dossiers
• Regional commercialization rights
• Patent licenses
• Supply of coated tablets or enteric-polymer intermediates

The most defensible asset is likely process know-how that reduces coating variability and improves yield. A simple list of excipients has limited standalone licensing value because most ingredients are commoditized and broadly used.

What is the revenue exposure and market opportunity?

Atelvia revenue exposure depends on product availability, reimbursement, generic entry, and the size of the oral bisphosphonate market. Brand revenue is vulnerable because:

• The active ingredient is mature.
• The product has a single principal strength.
• Immediate-release generic substitutes are available.
• Osteoporosis treatment has multiple therapeutic alternatives.
• Payers may not reimburse a premium for delayed-release dosing.

The opportunity for a follow-on manufacturer is more attractive than the opportunity for a premium brand strategy. A successful product could compete through:

• Lower acquisition cost
• Reliable weekly dosing
• Calendar packaging
• Broad pharmacy distribution
• Contract-manufacturing efficiency
• Regional launch sequencing

Which geographic markets are most attractive?

The commercial case varies by jurisdiction.

United States

The U.S. opportunity depends on Orange Book listings, ANDA approval, patent certifications, and reimbursement. FDA approval of the reference product does not eliminate formulation-specific patent risk.

European Union

European opportunities depend on national authorization strategy, reference-product status, supplementary protection certificate history, and country-level reimbursement. Enteric-coated risedronate may require country-specific commercial positioning because reimbursement systems differ.

Emerging markets

Markets with limited access to injectable osteoporosis therapies may favor a lower-cost oral delayed-release product. Local opportunities depend on registration requirements, manufacturing localization, tender systems, and intellectual-property enforcement.

Key Takeaways

• Atelvia is a 35 mg delayed-release risedronate sodium tablet approved for postmenopausal osteoporosis.
• Its core commercial differentiation is post-breakfast administration through enteric release.
• The formulation uses a conventional tablet core with a methacrylic-acid-based enteric coating system.
• The main development opportunity is coating-process optimization, not active-ingredient innovation.
• Generic competition must address delayed-release performance, not only risedronate chemical equivalence.
• The strongest IP questions concern formulation, dissolution, administration, and manufacturing claims.
• Immediate-release generic risedronate creates substantial substitution pressure.
• Packaging, adherence support, and low-cost coating manufacture are practical commercial differentiators.
• Licensing value is more likely to reside in process know-how, analytical methods, and regulatory packages than in individual excipients.
• Current generic-entry timing depends on the active Orange Book record, patent certifications, litigation, and any settlement agreements.

FAQs

Is Atelvia the same as generic risedronate?

No. Atelvia is delayed-release risedronate sodium. Immediate-release generic risedronate has different administration instructions and does not automatically qualify as an Atelvia equivalent.

Which excipient is most important in Atelvia?

The enteric polymer system is the most commercially important excipient group because it controls acid resistance and intestinal release. Methacrylic acid copolymer, plasticizer, talc, and coating-process conditions jointly determine performance.

Can a generic manufacturer use different excipients from Atelvia?

Yes, provided the product satisfies applicable pharmaceutical-equivalence, bioequivalence, quality, stability, labeling, and regulatory requirements. Different excipients may create additional formulation and performance risks.

Does Atelvia have biosimilar risk?

No. Atelvia contains a chemically synthesized small-molecule active ingredient. Competition would arise through generic or follow-on drug pathways, not biosimilar approval.

Is an enteric-coated risedronate tablet automatically patent-infringing?

No. Infringement depends on the specific patent claims, the accused formulation and process, the product’s release characteristics, and any applicable method-of-use claims.

References

1. U.S. Food and Drug Administration. (2010). Atelvia (risedronate sodium) delayed-release tablets: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022560s000lbl.pdf

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application regulatory review and approval resources. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

4. Federal Trade Commission. (n.d.). Pay-for-delay: Pharmaceutical patent settlement agreements. https://www.ftc.gov/legal-library/browse/competition/healthcare/pharmaceuticals/patent-settlements

5. U.S. Pharmacopeia. (2024). General chapter <711> dissolution. In United States Pharmacopeia and National Formulary. USP Convention.